SGLT2 inhibitors significantly improved eGFR trajectory in lithium-treated patients with mood disorders, indicating potential kidney function benefits.
Do SGLT2 inhibitors improve eGFR trajectory in patients with mood disorders receiving long-term lithium therapy?
SGLT2 inhibitors may mitigate lithium-associated kidney dysfunction in patients with mood disorders.
Absolute Event Rate: 0% vs 0%
SGLT2i treatment was associated with a significant improvement in eGFR trajectory in patients with mood disorders who received long-term lithium therapy. These findings suggest a potential role for SGLT2is in mitigating lithium-associated kidney dysfunction and highlight the need for randomized controlled trials in this population.
Ercis et al. (Sun,) reported a other. SGLT2 inhibitors significantly improved eGFR trajectory in lithium-treated patients with mood disorders, indicating potential kidney function benefits.